VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2021 | Beyond CGRP: psychedelics for the treatment of migraine

Calcitonin gene-related peptide (CGRP)-targeted therapies are at the center of attention in the migraine field, having demonstrated significant efficacy in the acute and preventive setting. Monoclonal antibodies and small molecules targeting CRGP and CGRP receptors have been developed and trialed, with several recently achieving FDA approval. Jessica Ailani, MD, MedStar Georgetown University Hospital, Georgetown, Washington, DC, shares her thoughts on the future of migraine treatment beyond CGRP. While the CGRP pathway is known to play a pivotal role in migraine pathophysiology, migraine is complex, and several other systems are involved. One area of exploration is the use of psychedelics. Small trials and case reports have suggested agents such as ketamine, LSD, and psilocybin may be of use for migraine treatment. More clinical trial-based research is needed in this area. This interview took place during the European Academy of Neurology 2021 congress.

Disclosures

Consulting: (Honoraria for independent consulting) Amgen, Abbvie, Biohaven, Eli Lilly and Company, Lundbeck, Teva, Impel, Satsuma, Theranica, Axsome, Neso, GlaxoSmithKline, Aeon, Medscape
Ownership of Stocks: CtrlM
Speakers Bureau: (Honoraria for promotional speaking) Allergan/Abbvie, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, Teva
Editorial services: (Honoraria) Current Pain and Headache Reports, Section editor, Unusual Headache Syndromes, NeurologyLive, SELF (medical reviewer)
Clinical Trial Grants: (Fees to Institution) American Migraine Foundation, Allergan, Biohaven, Eli Lilly and Company, Satsuma, Zosano